A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Vishnu Eshwar, Ashwin Kamath, Rajeshwari Shastry, Ashok K. Shenoy, Priyanka Kamath
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2022-11-01
סדרה:	Pharmaceuticals
נושאים:	secukinumab interleukin 17 adverse event psoriasis inflammatory bowel disease
גישה מקוונת:	https://www.mdpi.com/1424-8247/15/11/1365
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!